Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS
NCT03223961Phase 3Active, not recruiting
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Mar 2018
- Primary completion
- Sep 2023
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epoetin alfa in anemia (2 arms), sponsored by Groupe Français des Myélodysplasies. Primary endpoint: Time to Red Blood Cell transfusion dependence at 12 weeks. Started Mar 2018; status: active, not recruiting.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT03223961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03223961.